Lymphoma

Haplo-identical Haematopoietic Stem Cell Transplantation in Refractory Hodgkin Lymphoma After Carmustine, Etoposide, Cytarabine, Melphalan Conditioning Regimen

touchREVIEWS in Oncology & Haematology. 2021;17(2):Online ahead of journal publication

Allogeneic haematopoietic stem cell transplant (allo-HSCT) remains a potential curative therapeutic option for patients with refractory/relapsed Hodgkin lymphoma (HL) in whom an autologous peripheral blood stem-cell transplantation (PBSCT) has failed. This is explained by the additional benefit of a graft-versus-lymphoma (GVL) effect. Unfortunately, HLA-identical donors are not available for all patients. In such cases, haplo-identical […]

Treatment of Hodgkin Lymphoma – New and Developing Therapies and Their Potential Role in Standard of Care

European Oncology and Haematology. 2019:15(1):53–63 DOI: https://doi.org/10.17925/EOH.2019.15.1.53

Hodgkin lymphoma is a B-cell lymphoma that predominantly affects adults between 20–40 years of age, with a second incidence peak in those 55 years of age or older.1,2 It is also the most common form of lymphoma in adolescents, occurring in nearly two-thirds of patients with lymphoma between the ages of 15–19.3 Overall, the annual incidence of […]

Chimeric Antigen Receptor T-cell Therapy for Relapsed or Refractory Large B-cell Lymphoma – Latest Data from the ZUMA-1 Study

European Oncology & Haematology, 2019;15(1):16–7 DOI: https://doi.org/10.17925/EOH.2019.15.1.16

Large B-cell lymphoma includes diffuse large B-cell lymphomas, primary mediastinal B-cell lymphoma and transformed follicular lymphoma. These have historically been treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). High-dose salvage chemotherapy and autologous stem-cell transplantation (SCT) can be used in case of relapse, however, patients who fail R-CHOP or relapse following SCT have a […]

Theodoros P Vassilakopoulos, MD, PhD, EHA 2019 – Exciting new developments in Hodgkin lymphoma

At the EHA conference in Amsterdam we are joined by Professor Theodoros P Vassilakopoulos to discuss the most exciting new developments in standards of care for Hodgkin lymphoma. Questions 1. What are the limitations of current standards of care for Hodgkin lymphoma (HL)? (0:05) 2. What is the role of brentuximab vedotin in the current […]

Andrea Gallamini, EHA 2019 – Three-year Update of the ECHELON-1 Study

We are joined by Andrea Gallamini, at EHA 2019 to discuss his presentation on frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Questions 1. Could you tell us a little about the ECHELON-1 study and its findings? (0:05) 2. What have we learned from the 3-year […]

Eva Domingo Domènech, EHA 2019 – The Phase II CHECKMATE 205 Study

We are joined by Eva Domingo Domènech at EHA 2019 to discuss her presentation on nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: 2-year extended follow-up from cohort D of the phase II CHECKMATE 205 study. Questions 1. What are the major unmet needs in the treatment of advanced stage […]

Current Therapeutic Options in Waldenström Macroglobulinemia

Oncology & Hematology Review. 2019;15(1):39–47 DOI: https://doi.org/10.17925/OHR.2019.15.1.39

Waldenström macroglobulinemia (WM) is an indolent lymphoma characterized by the presence of a circulating monoclonal immunoglobulin M (IgM) protein of any size and lymphoplasmacytic infiltrate in the bone marrow.1 It lies within a continuous spectrum of disorders associated with a monoclonal IgM protein in the serum, with the precursor disease, IgM monoclonal gammopathy of undetermined […]

Acalabrutinib in Mantle Cell Lymphoma – New Long-term Data Announced

Mantle cell lymphoma is an rare, aggressive B-cell lymphoma that accounts for around 6% of all non-Hodgkin’s lymphoma but is more common in patients who are aged 65 years and over.1 Its prognosis is poor, with a median overall survival (OS) of 4–5 years; however, outcomes vary widely, with some patients having very aggressive disease […]

Is RELEVANCE Relevant? Lenalomide Plus Rituximab is not More Effective Than Rituximab Plus Chemotherapy Followed by Rituximab in First-line Follicular Lymphoma

Insights into the RELEVANCE study presented at the 23rd Congress of the European Haematology Association, 14–17 June 2018, Stockholm, Sweden Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma and accounts for 15–30% of all lymphomas.1 The disease is characterised by recurrent relapses and remissions that become progressively shorter. The standard first-line treatment option […]